This study aims to compare the efficacy and safety of both types of lasers, Holmium MOSES and TFL, in management of kidney stones requiring treatment.
The prevalence of kidney stones has been increasing over the last two decades with lifetime recurrence risk reported to be as high as 50%. Holmium lasers are nowadays considered the "gold standard" for treatment of urinary tract stones. Recently, the holmium laser urology platform from Lumenis has been updated to include a new technology called MOSES, which provides improved energy delivery of the laser to treat the stones, reduces migration of the stone during the procedure, and limits potential collateral tissue damage. A new generation of lasers has evolved due to the advances in laser fiber technology, leading to the development of the Thulium Fiber Laser (TFL). TFL can operate within a large range of energy, frequency and pulse duration settings. The small fiber size is one of the main advantages of TFL, as it allows better endoscope performance through easier deflection and bigger working channel space. Furthermore, it produces small stone fragments and better dusting capabilities compared to the standard Holmium laser when adjusted on the same power settings. This study will compare the efficacy and safety of Holmium MOSES and TFL in management of kidney stones requiring treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
174
Participants will undergo treatment using the TFL
Participants will undergo treatment using the MOSES Holmium laser.
Thunder Bay Regional Health Sciences Centre
Thunder Bay, Ontario, Canada
RECRUITINGProcedural Time
Measured in number of minutes from the insertion of the ureteroscope to the removal of the ureteroscope.
Time frame: Intraoperative
Stone Free Rate (SFR)
SRF will be defined as the absence of any residual stone fragments or the presence of clinically insignificant residual stone fragments in the urinary tract which were defined as ˂4 mm, asymptomatic, non-obstructive and non-infectious stone particles.
Time frame: 4 and 12 weeks post-op
Total operative time
Measured in n minutes from the anesthesia induction until placement of the stent.
Time frame: Intraoperative
Lasing time
Measured in minutes and defined as the time the laser was in use, not including pedal pauses.
Time frame: Intraoperative
Total energy used
Measured in kilojoules, defined as energy used to fragment the stones into small pieces (≤2 mm).
Time frame: Intraoperative
Laser efficiency
Measured as mm per minute and defined as the stone size (mm) that can be treated every minute; the cumulative stone size (adding the maximum size of each stone that is treated during the surgery) is divided by the lasering time.
Time frame: Intraoperative
Number of times the laser pedals are pressed
Measured as a numerical value, defined as number of left, right, and total pedal presses
Time frame: Intraoperative
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Percentage of Patients with Post-op Complications
Percentage of patients that results with a post-op complication
Time frame: 4 weeks